| 215.98 8.15 (3.92%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 262.68  |
1-year : | 279 |
| Resists | First : | 224.9 |
Second : | 238.86 |
| Pivot price | 211.03 |
|||
| Supports | First : | 202.3 | Second : | 168.31 |
| MAs | MA(5) : | 208.27  |
MA(20) : | 215.25 |
| MA(100) : | 238.11 |
MA(250) : | 205.96 |
|
| MACD | MACD : | -6.7 |
Signal : | -7.4 |
| %K %D | K(14,3) : | 34 |
D(3) : | 18.2 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 266.38 | Low : | 128.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ JAZZ ] has closed below upper band by 16.3%. Bollinger Bands are 31.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 216.92 - 217.8 | 217.8 - 218.63 |
| Low: | 206.91 - 207.87 | 207.87 - 208.78 |
| Close: | 214.42 - 215.95 | 215.95 - 217.41 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Fri, 30 Oct 2026
JAZZ Q3'26 Earnings: EPS estimate is (4.05) USD - TradingView
Fri, 30 Oct 2026
Jazz Pharmaceuticals plc (JAZZ) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
Jazz Pharmaceuticals plc (JAZZ) Seasonal Returns Chart - Yahoo! Finance Canada
Thu, 29 Oct 2026
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Australia
Thu, 29 Oct 2026
Jazz Pharmaceuticals plc (JAZZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 27 Oct 2026
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 102.9 (%) |
| Shares Short | 5,480 (K) |
| Shares Short P.Month | 4,620 (K) |
| EPS | 14.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 74.09 |
| Profit Margin | 20.4 % |
| Operating Margin | 26.9 % |
| Return on Assets (ttm) | 6.8 % |
| Return on Equity (ttm) | 22.1 % |
| Qtrly Rev. Growth | 15.5 % |
| Gross Profit (p.s.) | 64.7 |
| Sales Per Share | 70.86 |
| EBITDA (p.s.) | 29.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,660 (M) |
| Levered Free Cash Flow | 1,430 (M) |
| PE Ratio | 14.8 |
| PEG Ratio | 0.9 |
| Price to Book value | 2.91 |
| Price to Sales | 3.04 |
| Price to Cash Flow | 8.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|